Skip to content

How is oral desensitization in patients with milk allergy

Assessment of the response to oral desensitization in patients with milk allergy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-2fbw8dt
Enrollment
Unknown
Registered
2022-03-26
Start date
2015-05-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immunotherapy

Interventions

Follow a group of 27 severe cow's milk protein allergy patients who underwent an oral milk immunotherapy protocol. Follow-up took place during the protocol and one year after the end of the protocol t
V03.175.500

Sponsors

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Lead Sponsor
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Collaborator

Eligibility

Age
3 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over three years old; diagnosis of persistent IgE-mediated cows milk allergy with compatible and reproducible immediate symptoms for less than one year or recent positive oral test (one year interval); severe cows milk allergy: as reported or recorded in the medical record of anaphylaxis history; specific IgE for milk, alpha-lactalbumin, beta-lactoglobulin or casein positive by the ImmunoCAP method; positive prick test with a diameter greater than or equal to three millimeters of the negative control for milk in natura; and possess self-injecting adrenaline

Exclusion criteria

Exclusion criteria: Patient diagnosed with cows milk allergy with some degree of tolerance; patient with non-IgE-mediated cows milk allergy; patient with eosinophilic esophagitis prior to immunotherapy; patients with uncontrolled asthma; patients with cardiovascular diseases or other diseases and therapies that contraindicated the use of adrenaline; patients with serious systemic diseases such as autoimmune diseases and malignant neoplasms; and patients and/or caregivers who have difficulty understanding the purpose of treatment, following treatment instructions, and recognizing and treating adverse reactions (not familiar with the action plan)

Design outcomes

Primary

MeasureTime frame
The expected outcome is for the patient to consume milk without reactions and reduction of clinical parameters

Secondary

MeasureTime frame
Secondary outcomes are not expected

Countries

Brazil

Contacts

Public Contactjuliana de Mendonça

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

juguima90@gmail.com+55(11) 2661-0000

Outcome results

None listed

Source: REBEC (via WHO ICTRP)